The GeparOLA study26 aimed to assess the efficacy and safety of neoadjuvant olaparib in combination with paclitaxel compared to carboplatin in patients with HER2-negative BC and homologous recombination deficiency. This evidence concerns the gene ERBB2 and breast cancer.